GENFLEET-B (02595) saw its shares rise over 6% during the trading session. At the time of reporting, the stock was up 4.62%, trading at HKD 35.80 with a turnover of HKD 17.952 million.

The latest announcement on the CDE website shows that GENFLEET-B's clinical trial application for the GFS202A injection was officially accepted on May 12, with the acceptance number CXSL2600491. Public information indicates that GFS202A is the world's first bispecific antibody targeting both GDF15 and IL-6.

Southwest Securities Co.,Ltd. (600369) published a research report stating that the company is targeting major therapeutic areas such as pancreatic cancer, non-small cell lung cancer, and cachexia with its product portfolio, aiming to cover first-line and various subsequent treatments, with its product development progress leading globally. The report forecasts revenues of RMB 85 million, RMB 102 million, and RMB 311 million for 2026, 2027, and 2028, representing year-on-year changes of -35%, +20%, and +205%, respectively. This marks the first coverage by the firm, which recommends active attention to the stock.